CeriBell (NASDAQ:CBLL) CEO Sells $145,753.36 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 6,068 shares of the stock in a transaction on Friday, August 21st. The shares were sold at an average price of $24.02, for a total value of $145,753.36. Following the completion of the transaction, the chief executive officer owned 781,731 shares of the company’s stock, valued at $18,777,178.62. The trade was a 0.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xingjuan Chao also recently made the following trade(s):

• On Wednesday, August 19th, Xingjuan Chao sold 31,415 shares of CeriBell stock. The shares were sold at an average price of $25.03, for a total value of $786,317.45.
• On Tuesday, August 18th, Xingjuan Chao sold 2,199 shares of CeriBell stock. The stock was sold at an average price of $25.00, for a total value of $54,975.00.
• On Tuesday, July 7th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $19.90, for a total value of $776,100.00.
• On Monday, June 8th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $18.33, for a total value of $714,870.00.

CeriBell Stock Down 0.3%

Shares of NASDAQ CBLL opened at $23.37 on Friday. The company has a 50 day simple moving average of $20.00 and a 200 day simple moving average of $19.32. The firm has a market cap of $896.94 million, a PE ratio of -13.28 and a beta of 0.81. CeriBell, Inc. has a 1 year low of $10.85 and a 1 year high of $25.33. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%.The business had revenue of $28.10 million for the quarter, compared to the consensus estimate of $27.28 million. On average, research analysts forecast that CeriBell, Inc. will post -1.96 EPS for the current year.

Institutional Investors Weigh In On CeriBell

Institutional investors have recently modified their holdings of the company. Strs Ohio bought a new position in CeriBell during the first quarter worth $27,000. Caitong International Asset Management Co. Ltd lifted its holdings in CeriBell by 3,971.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after buying an additional 1,231 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in CeriBell during the third quarter valued at $33,000. CWM LLC grew its holdings in CeriBell by 1,178.5% during the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after acquiring an additional 1,697 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after acquiring an additional 1,801 shares during the period.

Analysts Set New Price Targets

A number of analysts recently weighed in on CBLL shares. Barclays upgraded CeriBell to a “neutral” rating in a report on Tuesday, August 18th. BTIG Research lifted their target price on CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Canaccord Genuity Group upped their price target on CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Finally, Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $22.40.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.